Amicus Therapeutics, Inc.
FOLD
Rang in aandelen
#3694
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery,... Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3. The latter is currently undergoing Phase 1/2 clinical studies to evaluate the safety and efficacy of a single intrathecal administration in patients with CLN3. Additionally, Amicus is exploring therapeutic approaches related to CDKL5, a gene on the X-chromosome that encodes a protein essential for regulating proper brain development. Amicus maintains strategic collaborations and licensing arrangements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.
Aandeelprijs
$14.49
Laatst gesynchroniseerd: 2026-04-27
Marktkapitalisatie
$4.55B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
71.68%
Land
US
Handel Amicus Therapeutics, Inc. (FOLD)
Categorie
Healthcare
P/S-ratio voor Amicus Therapeutics, Inc. (FOLD)
P/S-ratio op October 2026 TTM: 8.94
Volgens de meest recente financiële rapporten en aandelenkoers van Amicus Therapeutics, Inc. is de huidige P/S-ratio (TTM) 8.94. Eind 2023 had het bedrijf een P/S-ratio van 10.49.
P/S-ratiohistoriek voor Amicus Therapeutics, Inc. van 2003 tot 2026
P/S-ratio aan het einde van elk jaar
| Jaar | P/S-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 8.94 | 64.63% |
| 2024 | 5.43 | -48.25% |
| 2023 | 10.49 | -2.17% |
| 2022 | 10.72 | 4.47% |
| 2021 | 10.26 | -55.21% |
| 2020 | 22.91 | 78.30% |
| 2019 | 12.85 | -34.13% |
| 2018 | 19.51 | -67.36% |
| 2017 | 59.76 | -55.65% |
| 2016 | 134.73 | 0.00% |
| 2015 | 0.00 | -100.00% |
| 2014 | 506.03 | 52.41% |
| 2013 | 332.02 | 4,905.76% |
| 2012 | 6.63 | 19.55% |
| 2011 | 5.55 | -96.08% |
| 2010 | 141.38 | 10,030.50% |
| 2009 | 1.40 | -88.36% |
| 2008 | 11.99 | -84.96% |
| 2007 | 79.76 | 0.00% |
| 2006 | 0.00 | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
P/S-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/S-ratio | Verschil in P/S-ratio | Land |
|---|---|---|---|
| 10.02 | 12.11% |
US
|
|
| 40.55 | 353.61% |
US
|
|
| 3.96 | -55.69% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 13.50% |
NL
|
